MOG and glioblastoma: Choe et al. tested a SynNotch-CAR to target specific antigens for glioblastoma, such as the variable but tumour-specific glioblastoma neoantigen epidermal growth factor receptor variant III (EGFRvIII), the tissue-specific antigen for the central nervous system (CNS), and the myelin oligodendrocyte glycoprotein (MOG).